The Medical and Cognitive Research Unit located at Austin the Austin Repatriation Hospital is the largest dementia clinical trials site in the southern hemisphere and one of the largest in the world. Currently we are conducting 27 trials at with patients at various stages of Alzheimer’s Disease. Of the 27 Trials at our site: 10 are actively recruiting, 5 trials that are closed to recruitment with patients ongoing, 5 trials are pending approval and will be open to recruitment in by November 2015 and 5 trials in the selection process.
Trials currently run at MCRU (and investigational drug used)
A4 Study (solanezumab, an anti-amyloid monoclonal antibody)
Anti-Amyloid Treatment in Asymptomatic Alzheimer's Disease
A Randomized, Double-Blind, Placebo-Controlled, Sequential Cohort, Multi-Center Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of F03 in Participants with Mild Cognitive Impairment due to Alzheimer’s Disease.
DIAN (solanezumab, an anti-amyloid monoclonal antibody)
A Phase II/III Randomized, Double-Blind, Placebo-Controlled Multi-Center Study of 2 Potential Disease Modifying Therapies in Individuals at Risk for and with Dominantly Inherited Alzheimer’s disease
FORUM (EVP-6124, an alpha-7 nicotinic agonist)
A 26-Week Extension Study of the Safety and Clinical Effects of EVP-6124 in Participants with Alzheimer’s disease Currently or Previously Receiving an Acetylcholinesterase Inhibitor Medication
Lunbeck / Starbright (idalopirdine, a 5-HT6 antagonist)
Randomised, double-blind, parallel-group, placebo-controlled study of Lu AE58054 in patients with mild-moderate Alzheimer’s disease treated with an acetylcholinesterase inhibitor; Study 3
Merck19- APECS (MK 8931, a beta amyloid cleaving enzyme inhibitor)
A Phase III, Randomized, Placebo-Controlled, Parallel-Group, Double-Blind Clinical Trial to Study the Efficacy and Safety of MK-8931 (SCH 900931) in Participants with Amnestic Mild Cognitive Impairment Due to Alzheimer’s Disease (Prodromal AD).
Merck 17- EPOCH(MK 8931, a beta amyloid cleaving enzyme inhibitor)
A clinical trial to determine the safety and efficacy of MK-8931 in Mild to Moderate Alzheimer’s Disease.
Marguerite Road (gantenerumab, an anti-amyloid monoclonal antibody)
A Phase III, randomised, double blind, placebo-controlled, parallel-group multicentre efficacy and safety study of Gantenerumab in patients with mild Alzheimer’s disease.
Amaranth / Astra Zeneca (JNJ-548619110,a beta amyloid cleaving enzyme inhibitor)
Astra Zeneca, D5010C00009, A 24-month, Multicentre, Randomized, Double-blind, Placebo-controlled, Parallel-group, Efficacy, Safety, Tolerability, Biomarker, and Pharmacokinetic Study of AZD3293 in Outpatients with Early Alzheimer’s Disease; PAREXEL number 216846
Anavex 9ANAVEX 2-73, a sigma 1- Mu receptor agonist)
A Phase IIa Study of ANAVEX2-73 Adaptive-Trial-Design with Repeated Doses, Maximum Tolerated Dose Finding, Pharmacodynamics Investigation and Bioavailability Evaluation in Patients with Mild to Moderate Alzheimer’s Disease With a 6-Month Open Label Follow-Up Period.
Biogen (aducanumab, an anti-amyloid monoclonal antibody)
A phase 3 Multicentre, randomised, double blind, placebo controlled, parallel-group study to evaluate the efficacy and safety of BIIB037 in Participants with early symptomatic Alzheimer's Disease.
Novartis / PPD (CAD106, an a-beta fragment to promote an immune response, and CNP520, a beta amyloid cleaving enzyme inhibitor)
A randomised double blind, placebo controlled, two cohort parallel group study to evaluate the efficacy of CAD106 and CNP520 in preclinical Alzheimer's disease participants at risk for the onset of clinical symptoms.
AZ Therapies (ibuprofen/sodium chromolyn)
A phase III safety and efficacy study of ALZT‐OP1 in Participants with evidence of early Alzheimer’s disease
Janssen Research & Development, LLC (JNJ-54861911,a beta amyloid cleaving enzyme inhibitor)
A Phase 2b/3 Randomized, Double-blind, Placebo-Controlled, Parallel Group, Multicentre Study Investigating the Efficacy and Safety of JNJ-54861911 in Participants who are Asymptomatic At Risk for Developing Alzheimer’s Dementia”
A Placebo-controlled, Double-blind, Parallel-group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Participants With Early Alzheimer’s Disease
Roche (crenezumab, an anti-amyloid monoclonal antibody)
A Phase III, Multicentre, randomized, double-blinded, placebo-controlled, parallel-group, efficacy and safety study with open-label extension of crenezumab in patients with prodromal -to-mild Alzheimer’s Disease.
Axovant Sciences, Inc. (RVT-101, a 5HT6 receptor antagonist)
A Phase 3, double blind, randomized study of RVT-101 versus placebo when added to existing stable donepezil treatment in Participants with mild to moderate Alzheimer’s disease.
Our Friendly Staff Members
Associate Professor Michael Woodward – MCRU Medical Director
Dr Henry Zeimer –Consultant Geriatrician
Dr Cilla Haywood – Consultant Geriatrician
Dr Ronald Scholes – Consultant Geriatrician
Dr Irene Tan – Consultant Geriatrician
Dr Paul Yates – Consultant Geriatrician
Kathy Skoff – MCRU Manager
Kristin Cooper – Study Coordinator
Carolyn Baker – Study Coordinator
Jenny Kaiser – Study Coordinator
Lauren Grimwood – Study Coordinator
Vasantha Pather Lowen – Study Coordinator
Sylvia Griek – Study Coordinator
Su Jin Smith – Study Coordinator
Tara O’Donoghue- Study Coordinator
Beatriz Webb – Research Administration Assistant